Pagliuca Simona, Malard Florent, Mooyaart Jarl E, Daskalakis Michael, Gabellier Ludovic, Yakoub-Agha Ibrahim, Ram Ron, Besley Caroline, Forcade Edouard, Vucinic Vladan, Corral Lucía López, Vydra Jan, von Tresckow Bastian, Amat Paula, Amrolia Persis, Vandenberghe Peter, Stölzel Friedrich, Sica Simona, Rubio Marie Thérèse, Hoogenboom Jorinde D, Ortiz-Maldonado Valentín, Nagler Arnon, Kuball Jürgen, Chabannon Christian, Ruggeri Annalisa
Hematology department, Nancy University Hospital, UMR 7365, CNRS, University of Lorraine, Vandoeuvre-lès-Nancy, France.
Sorbonne Université, Centre de Recherche Saint-Antoine INSERM UMRs938, Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France.
Blood Rev. 2025 May;71:101272. doi: 10.1016/j.blre.2025.101272. Epub 2025 Feb 15.
Immune monitoring of cell therapies is a complex and evolving topic, particularly in the rapid expanding field of chimeric antigen receptor T (CAR-T) cell applications. Defining essential, recommended, and optional immune monitoring data post-CAR-T cell infusion is crucial to improve patient outcomes and inform post-treatment decisions. To address this gap, we conducted a survey-based study across centers affiliated with the European Society for Blood and Marrow Transplantation (EBMT), focusing on patients treated with European Medicines Agency (EMA)-approved CAR-T products. Building on a thorough review of the literature, we mapped the current landscape of immune monitoring practices and assessed their impact on clinical management. By defining the state of the art in the field, this work marks an initial step towards a structured harmonization process potentially able to enhance the management and outcomes of patients undergoing these immune cell therapies.
细胞疗法的免疫监测是一个复杂且不断发展的主题，尤其是在嵌合抗原受体T（CAR-T）细胞应用迅速扩展的领域。定义CAR-T细胞输注后必要的、推荐的和可选的免疫监测数据对于改善患者预后和指导治疗后决策至关重要。为了填补这一空白，我们在欧洲血液和骨髓移植学会（EBMT）所属的各中心开展了一项基于调查的研究，重点关注接受欧洲药品管理局（EMA）批准的CAR-T产品治疗的患者。在对文献进行全面综述的基础上，我们梳理了免疫监测实践的现状，并评估了它们对临床管理的影响。通过界定该领域的技术水平，这项工作标志着朝着结构化协调进程迈出了第一步，该进程有可能改善接受这些免疫细胞疗法患者的管理和预后。
